Ziad Bakouny, MD, MSc
Postdoctoral Genitourinary Oncology Research Fellow
Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology Boston, Massachusetts
The current management of metastatic renal cell carcinoma (RCC) reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.
However, no overall survival (OS) benefit has yet been achieved with the use of systemic agents in the localized disease context when therapy with curative intent is often still possible.1
This is an important unmet need, because the risk of relapse can be as high as 80% in the most aggressive forms of the disease.2
Although adjuvant approaches employing VEGFR-directed tyrosine kinase inhibitors (TKIs) have largely been ineffective, innovative strategies based on immune checkpoint inhibition (ICI) may reshape the field of perioperative therapy for RCC.Targeted Therapies for Localized RCC Disappoint